SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
Published: 31 August 2022
-
Views:
51973
-
Likes:
7
-
Views:
51973
-
Likes:
7
-
12m 17sPart 5 Q&A and Discussion
-
18m 8sPart 1 SGLT2 Inhibitors: Light at the End of the Tunnel Scott Solomon, John JV McMurray, Carolyn Lam, Muthiah Vaduganathan
-
9m 53sPart 2 SGLT2 Inhibitors Across the Spectrum of Heart Failure John JV McMurray
-
11m 9s
Overview
During this unique broadcast, ‘SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure’, Radcliffe Medical Education brings together a globally-renowned faculty to participate in a discussion centred around the presentation of the latest SGLT-2 inhibition data and how this translates to the treatment of Heart Failure patients.
Presented, and recorded, at ESC Congress 2022 in Barcelona, this programme is now available to watch on-demand. The programme is chaired by Prof Scott Solomon (Boston, US), who is joined by Prof John McMurray (Glasgow, UK), Prof Carolyn Lam (Singapore, SG) and Dr Muthiah Vaduganathan (Boston, US) while they explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.
Learning Objectives
Upon participation in this programme, physicians will be able to:
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
This programme is intended to educate:
- Global cardiologists
- Heart Failure specialists
- Primary care physicians
- Nurses
- Pharmacists
More from this programme
Part 1
SGLT2 Inhibitors - Another piece of the Puzzle in Heart Failure
Part 2
SGLT2 Inhibitors Across the Spectrum of Heart Failure
Part 3
Practical Considerations for Treating HF With Mildly Reduced and Preserved EP
Part 4
Implementing Best Practices Across the Spectrum of Heart Failure
Part 5
Q&A and Discussion
| 1 session | |
| Q&A and Discussion | Watch now |
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.